For Healthcare Professionals & Professional Audiences · Refer to local product labelling and approved indications in your region. Conference Hub · April 2026

Explore the science, products and technologies behind Concept Medical Group. One mobile-first destination for healthcare professionals and professional audiences at every conference.

Conference Hub · 2026

See the Science.
Explore the Portfolio.
Discover the Group.

From SirPAD / NEJM evidence to Nanolute technology and Envision Scientific manufacturing. A smarter way to explore Concept Medical Group at conference.


01
Featured Science

Latest landmark clinical evidence from SirPAD, SIRONA, EASTBOURNE and TRANSFORM II supporting the MagicTouch platform across PAD and coronary artery disease.

HCP Notice: All clinical content is for informational purposes only. Approved public claims only. Refer to local product labelling and full publications for complete methodology and safety data.
SirPAD · NEJM · March 2026
SirPAD Primary Results · New England Journal of Medicine

Primary results confirm the safety and efficacy of the sirolimus-coated balloon in peripheral arterial disease. Published in the NEJM. Primary endpoint met.

SirPAD trial · MagicTouch PTA · PAD · NEJM peer-reviewed
SIRONA · RCT · TCT USA 2024
SIRONA · Sirolimus vs Paclitaxel Drug-Eluting Balloon Angioplasty in Femoropopliteal Artery

Head-to-head RCT in 482 patients across 25 sites. MagicTouch PTA achieved 73.8% primary patency vs 75% for paclitaxel DCBs (1.2% difference), meeting the non-inferiority endpoint. No significant difference in cdTLR at 12 months. 89% of patients improved by one or more Rutherford stage. Presented at TCT USA 2024 LBCT.

MagicTouch PTA · PAD · Femoropopliteal · RCT · 482 patients · 25 sites · TCT USA 2024 · JACC publication
EASTBOURNE · eurointervention - 2024
EASTBOURNE · Sirolimus-Coated Balloon in All-Comer Coronary Artery Disease

Prospective registry evaluating MagicTouch SCB in an all-comer coronary artery disease population. Provides real-world evidence across a broad spectrum of lesion types and patient profiles. Published in Eurointervention.

MagicTouch SCB · Coronary artery disease · All-comer prospective registry · JACC Cardiovascular Interventions
TRANSFORM II · RCT · Enrollment Complete · June 2025
TRANSFORM II · MagicTouch SCB vs Everolimus-Eluting Stent in De Novo Coronary Vessels

One of the largest global DCB RCTs. Enrollment of 1,832 patients completed June 2025 across 52 centres in Europe, Asia and South America. Compares MagicTouch SCB vs everolimus-eluting stent in de novo coronary lesions. Primary endpoint: Target Lesion Failure at 12 months, non-inferiority design. Follow-up up to 60 months. NCT04893291.

MagicTouch SCB · De novo coronary lesions · 1,832 patients · 52 centres · NCT04893291 · Enrollment completed June 2025
View All Clinical Evidence →

02
Portfolio Explorer

Explore the full Concept Medical Group portfolio across coronary, peripheral, access and specialty use cases.

DCB · Coronary
MagicTouch SCB
Sirolimus Coated Balloon Catheter

World's first Sirolimus Coated Balloon for targeted sub-micron drug delivery across the CAD spectrum. Indicated for ISR, small vessels, bifurcation and de-novo lesions. 2 US FDA IDE Approval for Small Vessels & In-Stent Restenosis Indications.

View product →
DCB · Access
MagicTouch AVF
Dialysis Access · Sirolimus Coated Balloon

Sirolimus-coated balloon for stenotic lesions of dysfunctional AV fistula and graft. Dedicated clinical trials and investigator programme for dialysis access patients.

View product →
DCB · Erectile Dysfunction
MagicTouch ED
Erectile Dysfunction · Sirolimus Coated Balloon

Sirolimus-coated balloon for vasculogenic erectile dysfunction in de-novo and restenotic lesions. A specialty innovation extending the MagicTouch platform.

View product →
DCB · Peripheral
MagicTouch PTA
Peripheral Sirolimus Coated Balloon

Peripheral sirolimus-coated balloon for SFA, BTK, popliteal and iliac arteries. SirPAD primary results published in NEJM 2026 confirming safety and efficacy in PAD.

View product →
DES
Abluminus DES+
Sirolimus Eluting Stent

Sirolimus-eluting stent for diabetes mellitus, acute myocardial infarction and symptomatic CAD. Powered by the Envisolution platform for better bioavailability and long-term outcomes.

View product →
DES
Abluminus np DES
Polymer-Free Sirolimus Eluting Stent

Polymer-free sirolimus-eluting stent with fusion-coating. Active STARS DAPT programme with first patient enrolled January 2026. Designed for reduced DAPT duration and improved healing.

View product →
Accessory
Midas PTA Dilatation Catheter
PTA Dilatation Catheter

Broad peripheral angioplasty solution including SFA, BTK and AV dialysis fistulae. Designed as a reliable adjunct dilatation device for complex peripheral and access workflows.

View product →
Accessory
Transport AC
Thrombus Aspiration Catheter

Rapid exchange thrombus aspiration catheter for central and peripheral circulatory use in PTCA, PTA and stenting procedures. Adjunct support across multiple indications.

View product →

03
Technology

Proprietary drug-delivery platforms connecting clinical intent with precise drug transfer, retention and healing behaviour.

🔬
Nanolute™
DCB Drug Delivery Platform

Advanced drug delivery technology enabling sustained, homogeneous sirolimus transfer from non-implantable balloon surfaces. Unique circumferential coating for 100% surface area coverage.

MagicTouch SCBMagicTouch PTAMagicTouch AVFMagicTouch ED
💊
Envisolution™
DES Coating Platform

Proprietary stent coating providing better bioavailability of sirolimus, supporting healing behaviour and long-term outcomes across the Abluminus DES family.

Abluminus DES+Abluminus np DES
🏭
Envision Scientific
Manufacturing & Quality

The group's manufacturing establishment responsible for production scale, quality systems, regulatory compliance and controlled facility operations across all product families.

Group-wideQuality-controlled
80+
Countries worldwide
45+
Clinical trial programmes
24,000+
Patients in evidence base
1M+
Patients treated worldwide
10+
Years of innovation
04
Envision Scientific & Facility Access

Manufacturing scale, quality systems and controlled facility access underpinning the Concept Medical Group portfolio.

Envision Scientific

Manufacturing establishment behind Concept Medical Group responsible for production scale, quality systems, regulatory compliance and controlled facility operations across DCB and DES product families.

Manufacturing scaleQuality-controlledGlobal supplyRegulatory-compliant
Virtual Access · Time-Limited
Request virtual facility access

12-hour or 24-hour time-limited virtual access to the manufacturing environment for registered professional visitors attending this conference.

24-hour access windowManufacturing tourQuality systemsRegistration required

05
Learn & Experience

Register interest in Concept Classroom or download product and clinical documentation.

Coming Soon
Concept Classroom

An education-first format connecting science, technique and applied learning for healthcare professionals. Register interest to receive updates at launch.

Documentation
Download & Resources

Access clinical updates, product brochures and approved publications for MagicTouch and Abluminus families.


06
Get in touch to know more

Book a meeting, reach medical information or connect with the right representative for your region.

Book a Meeting

Meet a Concept Medical representative at the conference or schedule a follow-up session post-event.

📅 Conference & virtual available
Book a meeting ↗
Mail Us

Reach the Concept Medical team directly for product queries, medical information or documentation requests.

🔬 Medical information team
Get in Touch with Our Team

Connect directly with our team for product details, clinical questions, or to be put in touch with the right person in your region.

📞 Get in touch with our team
Get in touch ↗